In vitro antimicrobial activity of temafloxacin and its therapeutic efficacy in respiratory infections

Akira Watanabe, Yoshihiro Honda, Yutaka Tokue, Naoto Kitamura, Satoru Shoji, Hiroaki Kikuchi, Masakichi Motomiya, Akira Watanabe, Yoshihiro Honda, Yutaka Tokue, Naoto Kitamura, Satoru Shoji, Hiroaki Kikuchi, Masakichi Motomiya, Mitsunobu Honma

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The in vitro antimicrobial activity of temafloxacin (TMFX), a new quinolone agent for oral use, was measured, and its therapeutic efficacy in respiratory infections was evaluated. The minimum inhibitory concentrations (MICs) of TMFX, ofloxacin (OFLX), ciprofloxacin (CPFX), tosufloxacin (TFLX), sparfloxacin (SPFX) and rifampicin (RFP) against 20 starains each of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and Mycobacterium avium, and 18 strains each of Haemophilus influenzae and Mycobacterium tuberculosis were determined by the micro-broth dilution method using the Dynatech MIC 2000 system. As shown by the MICs, TMFX was as active as OFLX against all of the species tested except S. marcescens, P. aeruginosa and M. avium. TMFX was somewhat less active than OFLX against S. marcescens and P. aeruginosa, and more active than OFLX against M. avium. A daily dose of 300 mg (3 cases) or 600 mg (5 cases) of TMFX was administered orally for 8~21 days (mean: 13.6 days) to 8 patients: 2 with acute bronchitis, one with Mycoplasma pneumoniae pneumonia and 5 with acute pneumonia. The clinical effects were good in all cases. Five strains were identified as causative organisms. Four strains were eradicated and one strain (S. aureus) was decreased in number by administration of TMFX. No clinical adverse effects were observed during treatment with TMFX. Proteinuria was observed in one patient and a transient elevation of serum transaminase in another two patients, in one of whom anemia was also observed. These adverse effects resolved after the completion of therapy. We conclude from the above results that TMFX is one of the most useful quinolone agents for oral use as a drug of first choice in the treatment of respiratory infections, especially in outpatient clinics.

    Original languageEnglish
    Pages (from-to)308-314
    Number of pages7
    JournalChemotherapy
    Volume41
    DOIs
    Publication statusPublished - 1993 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'In vitro antimicrobial activity of temafloxacin and its therapeutic efficacy in respiratory infections'. Together they form a unique fingerprint.

    Cite this